KSKenji Sugiu

Kenji Sugiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenji Sugiu has a total of 221 co-authors. Here are the top co-authors by number of shared publications:

  • Koji Tokunaga

    Department of Neurosurgery, Okayama City Municipal Hospital, Okayama, Japan

    28 shared publications
  • Isao Date

    Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan

    24 shared publications
  • Tomohito Hishikawa

    Department of Neurological Surgery, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan

    23 shared publications
  • Masafumi Hiramatsu

    Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    20 shared publications
  • Isao Date

    Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    12 shared publications
  • Takashi Ohmoto

    11 shared publications

Latest Publications

  • Open Access

    Quantitative volumetric and lesion length analysis for evaluating the severity of intracranial vertebrobasilar dolichoectasia

    by Masakazu Okawa, Akira Ishii, Yuki Ebisudani, Satoshi Murai, Kenji Sugiu, Yuji Agawa, Taketo Hatano, Mizuki Nakano, Takashi Izumi, Nobuyuki Sakai

    Background: Vertebrobasilar dolichoectasia (VBD) is a rare disease, and the pathogenesis and factors associated with its prognosis are still unclear. Despite the high incidence of enlargement, rupture, and ischemia, the therapeutic indication and strategy of VBD remain unestablished. This study aimed to identify the factors associated with the outcome of VBD and to investigate its current treatment. Methods: We retrospectively reviewed patients who were diagnosed with VBD at 39 institutions in Japan between 2010 and 2019. Results: A total of 114 cases were collected, and 96 cases were included in the analysis. The median age of the patients was 65 years, the median follow-up was 2.7 years, and the median time from the initial diagnosis was 5.0 years. A total of 40.3% of patients had a modified Rankin Scale (mRS) scale of 0–2, and 42.3% of patients had a mRS score of 5–6. In a multivariate analysis, a shorter lesion length ( P = 0.033) and smaller vertebrobasilar (VB) artery volume ( P = 0.008) were significantly associated with a favorable outcome. A longer lesion length ( P = 0.004), larger VB artery volume ( P = 0.045), and therapeutic intervention for an aneurysm ( P = 0.04) were significantly associated with unfavorable outcomes. Conclusion: The lesion length and VB artery volume are independent factors associated with the outcome of VBD. The treatment of aneurysms is still challenging, and indications for treatment should be carefully determined.

  • Thirteen-Year Trends and Advancements of Endovascular Therapy for Dural Arteriovenous Fistulas in Japan: Insights from a Nationwide Study of 6470 Procedures

    by Satoshi Murai, Tomohito Hishikawa, Masafumi Hiramatsu, Jun Haruma, Kenji Sugiu, Koji Iihara, Hirotoshi Imamura, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, et al.

    BACKGROUND AND PURPOSE: Endovascular therapy (EVT) for dural arteriovenous fistulas (dAVFs) has evolved with advancements in imaging technology and devices. However, few large-scale, nationwide studies have been reported. This study aimed to investigate the trends and advancements in EVT for dAVFs over the past 13 years. MATERIALS AND METHODS: We identified patients from the Japanese Registry of Neuroendovascular Therapy (JR-NET) database treated for dAVFs between 2007 and 2019. We compared patient demographics, disease characteristics, treatment methods, and outcomes between JR-NET2 (2007–2009), JR-NET3 (2010–2014) and JR-NET4 (2015–2019). Predictive factors of complications were evaluated using multivariate logistic regression analysis. RESULTS: In total, we analyzed 6,470 procedures. Comparing JR-NET2, 3, and 4, the treatment for tentorial and anterior cranial fossa dAVFs has increased, and the use of precipitating liquid materials in transarterial embolization (TAE) increased to 31.7%. Complete obliteration in TAE alone increased to 38.0%, with no significant changes in complication rates, morbidity, or mortality at 30 days. In JR-NET2&3, complications were significantly associated with the cavernous sinus, tentorium, anterior cranial fossa, and emergency treatment. In JR-NET4, aggressive symptoms and precipitating liquid embolic materials were significantly correlated with complications. Supervision by senior trainers significantly reduced complications. CONCLUSIONS: The use of precipitating liquid embolic materials has improved TAE outcomes. While their use has also emerged as a new risk factor for complications, supervision by senior trainers has been shown to mitigate these risks. ABBREVIATIONS: CVR = cortical venous reflux; dAVFs = dural arteriovenous fistulas; EVT = endovascular therapy; JR-NET = Japanese Registry of Neuroendovascular Therapy = JSNET, Japanese Society for Neuroendovascular Therapy; TAE = transarterial embolization; TVE = transvenous embolization.


  • Open Access

    E-065 Interim safety and occlusion outcomes of endovascular treatment of large intracranial aneurysms in the sterling registry

    by O Zaidat, Y Ashouri, R Starke, A Puri, B Jankowitz, A Yoo, G Marnat, Z Kulcsar, K Sugiu, S Jahshan, et al.

    Introduction Endovascular treatment for intracranial aneurysms has been evolving. Since the results of the ISAT and BRAT trial were published, multiple advancement of endovascular devices and procedures have occurred. The aim of this study is to share interim results for large aneurysms (> 10 mm) treated within the STERLING registry. Methods The STERLING registry (NCT03642639) is a Prospective, Multi-center, Single Arm Study to Obtain ’Real World’ Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms (Cerenovus, Irvine, CA). The primary endpoint was adequate occlusion rate without retreatment at 12 months measured by Independent Core Lab. Secondary outcome measures were packing density, good functional outcome (mRS 0-2), as well as device-related serious events and retreatment rate within 1-year. Results Among the 450 subjects in the STERLING interim analysis, 44 patients had large aneurysms. Mean (Standard Deviation [SD]) age was 60.6(11.35), and most patients were females (77.3%). Hypertension was prevalent in (59.1%) of the cohort, while half of the cohort were smokers and (13.6%) had a history of SAH. Baseline mRS score was 0 and 1 in 61.4% and 27.3%, respectively. Mean (SD) aneurysm height and width were 11.06 mm (3.78) and 10.67 mm (3.44), respectively. Most aneurysms were in the anterior circulation (84.1%) and (61.9%) were sidewall. Median (IQR) dome to neck ratio was 2.0 (1.70-2.65) and 35 (79.5%) aneurysms had a wide neck. Saccular aneurysm was the most common morphology (86.4%) and (27.3%) were ruptured aneurysms. Most common method of treatment was primary coiling (n=16) followed by coiling+flow diversion (n=12). Mean (SD) packing density was 16.8(8.88). Adequate occlusion on 1-year follow-up was achieved in 86.7% (13/15) and four patients required retreatment within 1-year, resulting in 66.7% (10/15) patients with adequate occlusion without retreatment. There was no occurrence of intraprocedural rupture nor symptomatic intraprocedural thromboembolic events. Clinical outcome was available for unruptured aneurysms for 1 year follow-up and good functional outcome was achieved in 85.7% (12/14). Device related significant adverse events occurred in 1 patient only (2.3%). Conclusion Early results from the STERLING registry for large aneurysms are promising. Adequate occlusion per Independent Core Lab was achieved in 86.7% and retreatment rates were relatively low over 1-year follow-up. A good functional outcome was achieved in 85.7% of patients Disclosures O. Zaidat: 1; C; Stryker, Medtronic, Cerenovus, Penumbra, and Genentech. 2; C; Stryker, Medtronic, Cerenovus, Penumbra, and Neuravi. 4; C; ownership interest in Galaxy Therapeutics LLC;. 6; C; honoraria from Codman,Stryker,Penumbra, Medtronic. serves on the endovascular committee as co-chair for NIH StrokeNet Consortium; has served as an expert witness; had a patent for Ischemic stroke.. Y. Ashouri: None. R. Starke: 2; C; Medtronic Neurovascular, Penumbra, Cerenovus, Abbott.,. A. Puri: 1; C; Stryker Neurovascular, Medtronic, Cerenovus. He has received NIH grants. 2; C; tryker Neurovascular, Medtronic, Cerenovus, Microvention, QApel, Perfuze Medical, Arsenal Medical, Merit Medical Agile, Corindus, Imperative Care. 4; C; InNeuroCo Inc, Galaxy therapeutics, Agile Medical, Perfuze medical and Neurotechnology Investors. B. Jankowitz: None. A. Yoo: 1; C; Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. 2; C; Cerenovus, Penumbra, and Zoll. 6; C; Equity interest in Insera Therapeutics. G. Marnat: None. Z. Kulcsar: None. K. Sugiu: None. S. Jahshan: None. P. Machi: None. G. Pero: None. S. Castro: None. J. Howington,: None. C. Schirmer: None. C. Kilburg: None. C. Chivot: None. F. Al-Mufti: None. V. Da Ros: None. B. Gory: None. T. Yao: 2; C; Medtronic. A. Polifka: None. O. Francois,: None. A. Evans: None. J. Machaj: None. R. De Leacy: 2; C; Imperative Care, Cerenovus, Siemens Healthineers, Penumbra. 6; C; equity in Synchron, Endostream, Q’Apel Medical, Spartan Micro, Vastrax.

  • Open Access

    Questionnaire Survey of Neurointerventional Simulation Training in the Japanese Society for Neuroendovascular Therapy

    by Yuki Ebisudani, Kenji Sugiu, Satoshi Murai, Jun Haruma, Masafumi Hiramatsu, Tomohito Hishikawa, Isao Date

    Objective: Simulation training has focused on education and practical training. However, the adoption rate of neurointerventional simulation training in Japan is unknown. Therefore, we sent a questionnaire survey form to consulting specialists from the Japanese Society for Neuroendovascular Therapy (JSNET) to clarify the actual simulation training situation and compare the differences between university hospitals and general hospitals in Japan.Methods: The questionnaire survey was conducted in 243 neurosurgical training facilities that had JSNET consulting specialists between May 31, 2021 and July 31, 2021. The questionnaire survey forms were distributed by Google Forms.Results: A total of 162 facilities responded to the survey (response rate: 66.7%; 35.2% from university hospitals and 64.8% from general hospitals). The adoption rate for simulation training was 53.7%, and it was significantly higher in the university hospitals than in the general hospitals (64.9% vs. 47.6%, p = 0.035). On the simulation effectiveness survey, more than 80% of respondents answered that the simulation training was a useful tool for upskill training. The open-ended question on interventional simulation training showed that there are limiting factors such as financial constraints. Additionally, respondents expressed a desire for a standard neurointerventional simulation training and education program.Conclusion: The adoption rate for simulation training was 53.7% in the training facilities of JSNET, and it was higher in the university hospitals than in the general hospitals. Most of the respondents answered that simulation training is an effective tool to improve neurointerventional skills. They also requested the establishment of simulation training programs and simulation tools.


  • Angioarchitecture of the Normal Lateral Spinal Artery and Craniocervical Junction Arteriovenous Fistula Using Contrast-enhanced Cone-beam CT

    by Masafumi Hiramatsu, Kenji Sugiu, Takao Yasuhara, Tomohito Hishikawa, Jun Haruma, Kazuhiko Nishi, Yoko Yamaoka, Yuki Ebisudani, Hisanori Edaki, Ryu Kimura, et al.

    Background and Purpose The lateral spinal artery (LSA) perfuses the dorsolateral part of the spinal cord at the craniocervical junction (CCJ). We analyzed the angioarchitecture of the normal LSA and CCJ arteriovenous fistula (AVF). Methods The first study included 26 patients with a cerebral aneurysm of the posterior circulation. Using slab maximum intensity projection (MIP) images from three-dimensional rotational angiography (3D-RA) and contrast-enhanced cone-beam CT (CE-CBCT), we analyzed the origin of the LSA, its anastomosis with the posterior inferior cerebellar artery (PICA), the point where it reaches the spinal cord, and the visualized range. In the second study, we analyzed the angioarchitecture and treatment results of 7 CCJAVF lesions treated in our department between 2016 and 2021. Results We visualized the normal LSA for all patients. In 23 patients with an intradural origin PICA, all LSAs originated from the C1 or C2 radicular artery, and 8 patients had an anastomosis with the PICA. In three patients with a C1 level origin PICA, all LSAs originated from the PICA. All LSAs reached the dorsolateral part of the spinal cord. The mean visualized range of the LSA was 27.4 mm. The LSA was involved in five of seven CCJAVF lesions (71%). There was one lesion with a spinal infarction after LSA embolization. Other lesions were treated by direct interruption of the AVF, and the ASA and LSA were preserved. Conclusion This is the first report that visualized the LSA’s normal anatomy using slab MIP images from 3D-RA and CE-CBCT. Knowledge of LSA anatomy is critical to avoid complications during the treatment of CCJAVF.


  • Open Access

    Hemifacial spasm due to vertebral artery dissecting aneurysm treated with stent-in-stent placement; Pre- and post-treatment evaluation by 3D multifusion imaging using silent MR angiography

    by Toru Satoh, Yu Sato, Kenji Sugiu, Tomohito Hishikawa, Masafumi Hiramatsu, Jun Haruma, Isao Date

    Background: Hemifacial spasm (HFS) due to vertebral artery (VA) dissecting aneurysm (VADA) is rare and endovascular treatment has been performed in selected cases. Case Description: We encountered a case of HFS caused by VADA that was managed with endovascular stent placement and additional stent-in-stent placement. Therapeutic strategies and benefits based on pre- and post-treatment evaluation by 3D multifusion imaging using silent MRA were discussed. Conclusion: This is the first case report of stent-in-stent placement in successful treatment of HFS caused by VADA, in which relief of neurovascular contact was demonstrated by multifusion imaging.


  • A case of delayed foreshortening and disconnection of pipeline embolization device detected by chronological cone-beam computed tomography fusion image

    by Yuki Ebisudani, Kenji Sugiu, Jun Haruma, Satoshi Murai, Tomohito Hishikawa, Masafumi Hiramatsu, Yu Takahashi, Kazuhiko Nishi, Yoko Yamaoka, Yu Sato, et al.

    Objective The morphological changes of the pipeline embolization device (PED; Medtronic, Minneapolis, MN, USA), such as delayed migration or foreshortening, can relate to the incomplete occlusion of aneurysms. Case presentation A 30-year-old man with a giant cavernous carotid artery aneurysm was treated with two PEDs using the overlapping technique. Six months after treatment, follow-up angiography showed morphological changes of the PEDs and residual flow into the aneurysm. Chronological cone-beam computed tomography fusion imaging clearly revealed the dynamic foreshortening of the first PED and the disconnection of both PEDs, so we decided to implant an additional PED. Conclusion This case illustrates that a three-dimensional understanding can be useful for assessing the cause of treatment failure or recurrence.


  • A New Method of Intracranial Aneurysm Modeling for Stereolithography Apparatus 3D Printer: The “Wall-Carving Technique” Using Digital Imaging and Communications in Medicine Data

    by Jun Haruma, Kenji Sugiu, Minori Hoshika, Masafumi Hiramatsu, Tomohito Hishikawa, Satoshi Murai, Kazuhiko Nishi, Yoko Yamaoka, Yu Sato, Yuki Ebisudani, et al.


  • Mobile endovascular therapy for acute treatment of ruptured vertebral artery dissecting aneurysm in multiple hospitals

    by Naoya Kidani, Kenji Sugiu, Kaoru Terasaka, Hiroyuki Nakashima, Koji Tokunaga, Kazuki Kobayashi, Hirokazu Kambara, Tomohito Hishikawa, Masafumi Hiramatsu, Isao Date

    Background The patients with ruptured vertebral artery dissecting aneurysm (rVADA) should be treated as early as possible because VADA carries extremely high risk of rebleeding in the acute phase. We have established a mobile endovascular strategy for the patients with rVADA between our flagship center and its affiliated local hospitals. We introduced and reviewed our mobile endovascular therapy in this study. Methods We retrospectively evaluated 98 consecutive patients who underwent endovascular surgery for rVADA from 2000 to 2018 at our institution or five affiliated hospitals. When each patient was initially transported to the local affiliated hospitals, neuroendovascular surgeons traveled directly to the affiliated hospital from the flagship center in order to treat the patient there. Clinical outcomes using modified Rankin Scale at 6 months after treatment, radiological results, and procedure-related complications were reviewed to justify our mobile endovascular strategy. Results All aneurysms were cured successfully by internal trapping. Favorable outcome was achieved in 61 patients (62.2%) even though 53 patients (54.1%) had presented with severe subarachnoid hemorrhage. Overall mortality rate, treatment-related mortality rate, and treatment related complication rate were 18.4% (18/98), 0%, and 16% (16/98), respectively. There were no differences in clinical and radiological outcomes between the patients treated in the flagship center and those who treated in the affiliated hospitals. Treatment in the affiliated hospital was not a predictive factor of unfavorable outcome in our multivariate analysis, and elderly age (≥ 60) was negatively associated with favorable outcome. Conclusions Our results prove the efficacy and safety of mobile endovascular therapy for the treatment of rVADA in the ultra-acute stage. Mobile endovascular therapy may work well in the acute treatment of rVADAs in the certain circumstance.


  • Trends in Incidence of Intracranial and Spinal Arteriovenous Shunts

    by Satoshi Murai, Masafumi Hiramatsu, Etsuji Suzuki, Ryota Ishibashi, Hiroki Takai, Yuko Miyazaki, Yuji Takasugi, Yoko Yamaoka, Kazuhiko Nishi, Yu Takahashi, et al.

    Background and Purpose: To date, the incidence of intracranial and spinal arteriovenous shunts has not been thoroughly investigated. We aimed to clarify recent trends in the rates of intracranial and spinal arteriovenous shunts in Japan. Methods: We conducted multicenter hospital-based surveillance at 8 core hospitals in Okayama Prefecture between April 1, 2009 and March 31, 2019. Patients who lived in Okayama and were diagnosed with cerebral arteriovenous malformations, dural arteriovenous fistulas (DAVFs), or spinal arteriovenous shunts (SAVSs) were enrolled. The incidence and temporal trends of each disease were calculated. Results: Among a total of 393 cranial and spinal arteriovenous shunts, 201 (51.1%) cases of DAVF, 155 (39.4%) cases of cerebral arteriovenous malformation, and 34 (8.7%) cases of SAVS were identified. The crude incidence rates between 2009 and 2019 were 2.040 per 100 000 person-years for all arteriovenous shunts, 0.805 for cerebral arteriovenous malformation, 1.044 for DAVF, and 0.177 for SAVS. The incidence of all types tended to increase over the decade, with a notable increase in incidence starting in 2012. Even after adjusting for population aging, the incidence of nonaggressive DAVF increased 6.0-fold while that of SAVS increased 4.4-fold from 2010 to 2018. Conclusions: In contrast to previous studies, we found that the incidence of DAVF is higher than that of cerebral arteriovenous malformation. Even after adjusting for population aging, all of the disease types tended to increase in incidence over the last decade, with an especially prominent increase in SAVSs and nonaggressive DAVFs. Various factors including population aging may affect an increase in DAVF and SAVS.